MASH: The Role of Primary Care Providers in the Growing Epidemic
Overview
Most patients with metabolic dysfunction-associated steatohepatitis (MASH) have no symptoms until the disease is advanced, so it’s often missed. Primary care providers are crucial for identifying MASLD/MASH and referring patients to specialists. Although liver biopsy is the gold standard for diagnosis, it carries risks, and noninvasive tests are available. To address rising rates and low awareness, education on noninvasive diagnostic methods, biomarkers, treatment guidelines, and care pathways is needed to manage MASH and metabolic disease better.
Learning objectives
After completing this series, you’ll gain improved:
- Competence in integrating tools into clinical practice to improve diagnosis, staging, and monitoring for patients living with MASH.
- Knowledge differentiating patients with a higher risk of fibrotic disease that would be more suited to specialist management, compared to patients with a low risk of fibrotic disease that may be adequately managed in a primary care setting in accordance with MASH guideline recommendations.
- Competence and performance managing underlying comorbid conditions that contribute to the decline in long-term outcomes for patients living with MASH.
Key dates
- Released date:
- Jan. 7, 2026
- Expiration date:
- Nov. 16, 2026
Supporter acknowledgement
This independent CME/CE activity is supported by an educational grant from Novo Nordisk.Agenda
All times are Eastern.
Session Heading 1: Lorem Ipsum Dolor sit Amet
10:00 a.m. - 5:00 p.m.
Session Sub-title 1
Person, PhD
10:00 - 11:00 a.m.
Session Sub-title 2
Person, PhD
11:00 - 12:00 midday
Session Sub-title 3
Person, PhD
12:00 - 1:00 p.m.
Session Heading 2: Lorem Ipsum Dolor sit Amet
10:00 a.m. - 5:00 p.m.
Session Sub-title 1
Person, PhD
10:00 - 11:00 a.m.
Session Sub-title 2
Person, PhD
11:00 - 12:00 midday
Session Sub-title 3
Person, PhD
12:00 - 1:00 p.m.
Course contents
Part I: Detecting MASH in Primary Care: Tools for Timely Diagnosis and Management — 30 minutes
Part II: Recognizing a “Silent” Disease podcast — 30 minutes
Part III: How to Treat and When to Refer podcast — 30 minutes
Supplement: Screening and Assessment of MASH in Primary Care pocket guide
Course faculty
Course Director
Arun Sanyal, MD
Professor of Medicine, Physiology, and Molecular Pathology
Virginia Commonwealth University
Mary Rinella, MD
Director, Metabolic and Fatty Liver Disease
University of Chicago
Faculty
Diana Barb, MD
Clinical Associate Professor, Division of Endocrinology, Diabetes, and Metabolism
University of Florida
Rita Basu, MD
Professor, Division of Endocrinology, Diabetes and Metabolism
University of Alabama at Birmingham
Kenneth Cusi, MD, FACP, FACE
Professor of Medicine, Department of Endocrinology
Jennifer L. Middleton MD, MPH, FAAFP
Associate Director, Riverside Methodist Hospital Family Medicine Residency Program
Columbus, Ohio
Eric Lawitz, MD, FAASLD, AGAF, FAPCR, CPI
Clinical Professor of Medicine, Medical Director, Texas Liver Institute
University of Texas Health San Antonio
Zobair M. Younossi, MD, MPH, FACG, FACP, AGAF, FAASLD
Professor and Chair, Department of Medicine
Inova Fairfax Medical Campus
Erin Westfall, DO
Assistant Professor, Department of Family Medicine and Community Health
University of Minnesota Medical School